US real-world study evaluates incretin exposure in resmetirom initiators
In a real-world US cohort of resmetirom initiators, over a third had recorded incretin exposure, but among those without prior incretin use, starting an incretin within 30 days of resmetirom was uncommon at about 5%. Among 6837 patients initiating resmetirom, 37.2% had a recorded incretin prescription, mostly before starting resmetirom (33.8%). In patients without incretin use in the prior 5 years, only 5.1% co-initiated an incretin within 30 days of resmetirom. Co-initiators had a higher mean body mass index and higher metformin use, but co-initiation was not clearly associated with diabetes or coded overweight or obesity. Online version: https://www.diabesityrounds.com/a/us-real-world-study-evaluates-incretin-exposure-in-resmetirom-initiators
Authors
- Diabesity Rounds
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24361221
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00